Based upon emerging evidence, preclinical models examining the potential of approaches targeting the mitochondrion (e.g., to inhibit mitochondrial permeability transition) and the aryl hydrocarbon receptor may be valuable in seeking new targeted therapies for treating and preventing adverse skeletal muscle impact in COPD patients. Here, AHR is linked to chronic obstructive pulmonary disease.